+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Therapeutic failure of primaquine and need for new medicines in radical cure of Plasmodium vivax



Therapeutic failure of primaquine and need for new medicines in radical cure of Plasmodium vivax



Acta Tropica 160: 35-38



Primaquine has been the drug of choice for the prevention of Plasmodium vivax relapse for more than 60 years. Primaquine tolerant strain of P. vivax was identified in 1944. Significant mortality and disease burden of P. vivax calls for the need of new drugs. Primaquine resistance is a complex issue, as the mechanism of resistance is not clear. Direct evidence of resistance to primaquine by hypnozoites has not yet been shown. There are some reports detailing risk of primaquine resistance in specific regions, but the overall distribution of primaquine resistance in P. vivax-infected people is largely unknown. Confounding factors contribute to treatment failures; such as inadequate doses, inappropriate dosing intervals, risk of reinfection, combinations with blood schizontocidals, and compliance. Therefore, primaquine resistance needs to be addressed along with additional important confounding factors. Tafenoquine is the most studied drug in replacing primaquine for the radical cure of P. vivax malaria. It has comparable efficacy with primaquine. The potential advantage of tafenoquine is better compliance with a single dose regimen. Rational use of primaquine can secure its effectiveness, but it is essential in the future to have better or similar alternatives to treat P. vivax.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059121920

Download citation: RISBibTeXText

PMID: 27109040

DOI: 10.1016/j.actatropica.2016.04.009


Related references

Primaquine for radical cure of Plasmodium vivax and Plasmodium ovale malaria: an observational survey (2008-2010). Journal of Travel Medicine 20(2): 134-136, 2013

Expanding the Use of Primaquine for the Radical Cure of Plasmodium vivax. Clinical Infectious Diseases 67(7): 1008-1009, 2018

Optimal primaquine use for radical cure of Plasmodium vivax and Plasmodium ovale malaria in Japanese travelers--A retrospective analysis. Travel Medicine and Infectious Disease 13(3): 235-240, 2016

Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malaria Journal 11: 280, 2012

A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand. American Journal of Tropical Medicine and Hygiene 82(4): 542-547, 2010

Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. American Journal of Tropical Medicine and Hygiene 62(3): 393-395, 2000

Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria. Plos Neglected Tropical Diseases 12(4): E0006440, 2018

Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. Bmc Medicine 13: 294, 2015

Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure. International Ophthalmology 39(8): 1767-1782, 2019

Therapeutic failure wtih chloroquine and primaquine in malaria by Plasmodium vivax. Enfermedades Infecciosas Y Microbiologia Clinica 16(10): 490-491, 1998

Therapeutic Assessment of Primaquine for Radical Cure of Plasmodium vivax Malaria at Primary and Tertiary Care Centres in Southwestern India. Korean Journal of Parasitology 54(6): 733-742, 2016

Failure to radical cure in Plasmodium vivax malaria. Revista Chilena de Infectologia 33(4): 468-471, 2016

Primaquine; a new drug for the radical cure of relapsing vivax malaria. Journal of the Medical Association of Georgia 41(4): 126, 1952

In vivo trial for evaluation of chloroquine sensitivity of Plasmodium vivax isolates from Rondonia and efficacy of a new therapeutic schedules of association with primaquine for the treatment of P vivax malaria. Memorias do Instituto Oswaldo Cruz 93(Suppl. 2): 59-60, 1998

Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon. American Journal of Tropical Medicine and Hygiene 82(6): 1017-1023, 2010